Inside the $3 billion biotech preparing to launch the first treatment for NASH, a silent disease that affects millions of Americans
NASH is a liver disease that affects millions of Americans. Researchers expect it to become the leading cause of liver transplants in the US within the next few years.But now, Intercept Pharmaceuticals is preparing to launch the first-ever treatment for NASH. The treatment still needs to be approved by US regulators.
Now 18 years into Intercept's story, Pruzanski is still at the helm as CEO and still based on the west side of Manhattan. And he's still arguing with skeptical investors and doctors about the potential market for his liver disease drug. The disease has been a hot topic in biotech for the past few years. As the biotech industry witnessed high-profile NASH failures last year, Intercept stood alone in succeeding.
The same drug, called Ocaliva, has already been approved to treat a rare liver disease at a price of about $84,000 a year, before rebates and discounts. For NASH, the company has applied for a distinct brand name that can carry a separate price. Pruzanski acknowledged the uncertainty surrounding not just Intercept's drug but the disease as a viable market. The investor debate ramped up after Intercept announced initial positive results a year ago, he said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Bed Bath & Beyond to invest $1 billion on share buybacks, debt reduction and store upgradesAfter a disappointing holiday season, Bed Bath & Beyond CEO Mark Tritton knows he still has plenty of work ahead of him to turn the business around.
Consulte Mais informação »
Bed Bath & Beyond CEO addresses over-cluttered stores - Business InsiderBed Bath & Beyond's new CEO admits that stores are so cluttered that customers are leaving without buying anything due to 'purchase paralysis'
Consulte Mais informação »
Business Insider Intelligence - Business Insider
Consulte Mais informação »
PRESENTING: The 31 buzziest logistics startups that VCs are watching in 2020 - Business InsiderRead Business Insider's exclusive, VC-sourced roundup of the buzziest logistics startups in the coming year.
Consulte Mais informação »
Tech CEOs' second-in-command: Sheryl Sandberg, Ted Sarandos, and more - Business InsiderFrom Sheryl Sandberg to Ted Sarandos, here are the high-powered executives who are 2nd-in-command to some of the biggest CEOs in tech
Consulte Mais informação »
Alan: French health tech startup CEO on transparency and growth - Business InsiderFrench health tech startup Alan has no meetings above 3 people, reveals employee salaries, and has low staff churn. Its CEO explains why it works.
Consulte Mais informação »